Biohaven Signed a $350M Deal. Nine Days Later, the FDA Called.

The other study, BHV7000-302, is in a trickier spot. Its existing patients will keep receiving treatment, but no new patients can join until Biohaven delivers the additional nonclinical studies the FDA wants. How long that takes will determine whether this is a speed bump or a detour.

A $795 Million Handshake, Reconsidered

Let's talk about the deal, because the timing makes it impossible not to.

SK Biopharmaceuticals agreed to pay Biohaven $350 million upfront, with another $50 million coming in 2027. On top of that: up to $150 million in development milestones plus royalties in the mid-teens to low-twenties on U.S. sales. SK also took on certain obligations to Knopp Biosciences, including up to $245 million in contingent milestones.

All told, the deal's headline value reaches $795 million. It's a big bet on opakalim's potential in epilepsy.

The question investors are asking now: did SK know about the rodent findings before signing? According to Biohaven, the metabolite data was reviewed during diligence, and the company believed it was a rodent-specific issue. The deal hadn't officially closed yet when the hold landed; antitrust and other conditions were still pending as of the 8-K filing.

Whether this changes the deal's economics, its closing timeline, or SK's enthusiasm remains to be seen. But it's a textbook example of why biotech dealmaking carries a unique kind of risk that no amount of due diligence can fully eliminate.

Why Opakalim Matters

BHV-7000 works by activating Kv7.2/7.3 potassium channels in the brain. Think of these channels as tiny pressure valves on overexcited neurons. In epilepsy, neurons fire too aggressively; opakalim helps keep them calm by enhancing a natural electrical current (called the M-current) that stabilizes brain activity.

Older drugs have tried targeting potassium channels before, but opakalim is designed to be more selective, meaning fewer off-target effects. Biohaven has been developing it for focal epilepsy (the most common type in adults), idiopathic generalized epilepsy, and even some psychiatric conditions like bipolar mania.

If the drug works, it could offer a genuinely new mechanism for patients who don't respond well to existing treatments. That's a big "if" right now, but it's exactly the kind of opportunity that justified an almost $800 million deal.

What Happens Next

Biohaven needs to run additional nonclinical studies to convince the FDA that the rodent metabolite finding doesn't predict a problem in humans. If the data is clean, enrollment resumes and the program gets back on track. If not, the regulatory path gets significantly harder.

RBC Capital Markets flagged that the enrollment pause could delay readouts and complicate the eventual approval process. Some analysts also noted that competitors (like Xenon Pharmaceuticals, which has its own epilepsy program) could benefit from any timeline slippage.

For Biohaven's broader strategy, the company has been streamlining its portfolio to focus on a handful of high-conviction programs: opakalim in epilepsy, BHV-1300 in autoimmune diseases like Graves' disease, and taldefgrobep alfa in obesity. The SK deal was supposed to convert the epilepsy platform into non-dilutive cash, freeing up resources for those other bets. That logic still holds, assuming the deal closes as planned.

The Bigger Lesson

Clinical holds triggered by rodent findings aren't automatic death sentences for drugs. The FDA regularly asks sponsors to fill in gaps, and many programs recover by showing the animal signal doesn't cross over to humans. The pattern in recent years has been clear: provide strong mechanistic data showing species-specific effects, and the agency will often lift the hold.

But "often" isn't "always." Programs with weak explanations or broader safety signals face prolonged holds, tougher labels, or outright discontinuation.

For now, Biohaven's fully enrolled pivotal trial keeps ticking toward a readout. More than 600 patients continue dosing in the broader program. And somewhere in a lab, researchers are running the studies that will determine whether a rat metabolite derails a near-billion-dollar bet on the future of epilepsy treatment.

That's biotech. You can do all the diligence in the world, sign the biggest check of the quarter, and still get a call from the FDA nine days later.

BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer

BridgeBio Oncology pulled its lead KRAS drug out of the lucrative first-line lung cancer race, shrinking from a 200,000-patient opportunity to roughly 50,000. The stock dropped 24% in a single session, and the competitive fallout is just getting started.